Home > Boards > US Listed > Biotechs > Blueprint Medicines Corporation (BPMC)

CAMBRIDGE, Mass., April 29, 2015 /PRNewswire/ -- Blueprint

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
protagonist12 Member Profile
 
Followed By 54
Posts 1,845
Boards Moderated 1
Alias Born 11/14/12
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 1/20/2022 8:08:59 AM
Blueprint Medicines Elevates Two Talented Leaders to its Executive Team PR Newswire (US) - 1/20/2022 8:00:00 AM
JMP Securities Thinks Blueprint Medicines’ Stock is Going to Recover TipRanks - 1/12/2022 1:40:36 PM
Blueprint Medicines expects FY21 revenue at high end of $170M-$180M guidance range Seeking Alpha - 1/10/2022 2:16:04 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/10/2022 8:28:30 AM
Blueprint Medicines Provides 2022 Portfolio Goals Targeting Expanded Precision Therapy Leadership PR Newswire (US) - 1/10/2022 8:00:00 AM
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire (US) - 1/6/2022 4:01:00 PM
JMP Securities Keeps Their Buy Rating on Blueprint Medicines (BPMC) TipRanks - 1/6/2022 12:15:42 AM
Blueprint Medicines names new CEO in leadership shakeup Seeking Alpha - 1/5/2022 8:40:26 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/5/2022 8:08:51 AM
Blueprint Medicines Announces CEO and Leadership Transition Plan PR Newswire (US) - 1/5/2022 8:00:00 AM
Blueprint Medicines completes acquisition of Lengo Therapeutics Seeking Alpha - 12/30/2021 9:16:43 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/30/2021 9:12:03 AM
Blueprint Medicines Completes Acquisition of Lengo Therapeutics PR Newswire (US) - 12/30/2021 8:51:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/23/2021 5:10:20 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/17/2021 4:03:38 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/15/2021 4:24:26 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/10/2021 4:26:35 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 12/10/2021 4:25:23 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/9/2021 4:03:19 PM
Blueprint Medicines Appoints Daniella Beckman to its Board of Directors PR Newswire (US) - 12/9/2021 4:01:00 PM
Blueprint Medicines grants non-qualified stock options to 13 new employees Seeking Alpha - 12/7/2021 4:08:25 PM
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire (US) - 12/7/2021 4:01:00 PM
Nature Medicine Publishes Results from Two Registration Studies of AYVAKIT® (avapritinib) Showing Sustained Benefits in Patients with Advanced Systemic Mastocytosis PR Newswire (US) - 12/6/2021 4:01:00 PM
Blueprint Medicines to acquire precision oncology company Lengo Therapeutics Seeking Alpha - 11/29/2021 8:00:26 AM
protagonist12   Wednesday, 04/29/15 08:33:57 PM
Re: None
Post # of 16 
CAMBRIDGE, Mass., April 29, 2015 /PRNewswire/ -- Blueprint Medicines today announced the pricing of its initial public offering of 8,145,834 shares of its common stock at a public offering price of $18.00 per share, before underwriting discounts and commissions. In addition, Blueprint Medicines granted the underwriters a 30-day option to purchase up to an additional 1,221,874 shares of its common stock at the same price. The shares are scheduled to begin trading on The NASDAQ Global Select Market on April 30, 2015 under the ticker symbol "BPMC."

Goldman, Sachs & Co. and Cowen and Company are acting as joint book-running managers for the offering. JMP Securities is acting as a co-manager for the offering. Wedbush PacGrow is also acting as a co-manager for the offering.

A registration statement relating to these securities has been filed with and was declared effective by the Securities and Exchange Commission on April 29, 2015. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering will be made only by means of a prospectus. A preliminary prospectus describing the terms of the offering has been filed with the Securities and Exchange Commission and forms a part of the effective registration statement. A copy of the final prospectus relating to the offering will be filed with the Securities and Exchange Commission and may be obtained, when available, from Goldman, Sachs & Co. by mail at 200 West Street, New York, New York 10282, Attention: Prospectus Department, by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com, and from Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, by telephone at (631) 274-2806, or by fax at (631) 254-7140.

Contact:
Investor Relations:
Beth DelGiacco
Stern Investor Relations, Inc.
212-362-1200
beth@sternir.com

Media:
Beth Keshishian
inVentiv Health PR
212-229-8417
beth.keshishian@inventivhealth.com

SOURCE Blueprint Medicines

http://www.prnewswire.com/news-releases/blueprint-medicines-announces-pricing-of-initial-public-offering-300074756.html

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences